Skip to content
Fear and GreedStocks35Crypto24
Start for free

Corcept Therapeutics stock

CORTNASDAQ

Corcept Therapeutics Incorporated, HealthcareISIN US2183521028

$73.71▼ $0.82 (−1.1%)Closing price of 12 Nov 2026

74Score 74 out of 100, Strong

Turn on early warning

Price and trend

47 / 100

Price history

−6.0% in one year

The chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.

Long-term trend

Below the 200-day line: the price is 3.5% below it.

Trend change

Since June 2026 the 50-day line has been above the 200-day line; the trend has turned up.

Momentum

Sharply down: the price has fallen very quickly lately (RSI 28).

Distance to the high

The price is 40% below its 52-week high. Largest decline in 20 years: 85% (October 2007 to February 2009).

Chart figures for advanced users
SMA 50$104.49
Average price of the last 50 trading days, shows the short-term trend.
SMA 200$76.36
Average price of the last 200 trading days, shows the long-term trend.
RSI (14)28
Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
MACDbelow the signal line
Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
Support$32.15
The lowest closing price of the last twelve months.
Resistance$123.57
The highest closing price of the last twelve months.
What would $1,000 in Corcept Therapeutics have become?Return triangle for Corcept Therapeutics
Market cap
$8.16B
Div. yield
no dividend
57.6
on reported earnings of the last twelve months
19.2
on earnings for the next twelve months ($3.89 per share)
Fair value
$124.28

Snapshot

Computed from the data by fixed rules, no AI

  • Corcept Therapeutics Incorporated belongs to the Medical (Pharmaceuticals) industry (United States) and, with a market value of $8.07B, is number 7 of 17 companies in its industry on MEQIRI.
  • In fiscal 2025 it reported revenue of $761.41M (up 12.8% year on year) and earnings of $99.65M (down 28.7%).
  • For fiscal 2026, analysts expect on average revenue of $1.15B (up 50.7%) and adjusted earnings per share of $2.07 (up 152.9%).
Show more
  • MEQIRI Score 74 out of 100 (Strong): rank 83 of 714 in Healthcare, median 53.
  • The P/E is 57 (Medical (Pharmaceuticals) median 35.1, own median of recent years 25.4).
  • Our model puts fair value at $124.28, with the price 40% below it.

In plain words

The numbers on this page in plain words, written by an AI

Strengths

  • Analysts expect strong earnings growthUp 59.2% a year through 2028 (estimates from 4 analysts).Growth 73
  • More cash than debtCash $370.7M, financial debt $8.99M.Stability 77
  • Below fair valuePrice 40% below the fair value of $124.28.Valuation 51

Weaknesses

  • Margin fallingOperating margin 5.9%, average of the prior years 28% (to 2024).
  • Volatile share priceVolatility 83% a year over the last 12 months.
  • Richly valuedP/E 57, Medical (Pharmaceuticals) median 35.1, own median 25.4.Valuation 51
74/ 100
MEQIRI Score
Strong

Its standout strengths are fundamentals and profitability, while technical analysis holds the score back.

Daily figure as of 12 Nov 2026

How the score is calculated

Score overview

Fundamentals are strong, with stable profits and strong cash generation.

Profit consistency100% of years
Cash conversion (free cash flow to earnings, 12 months)120%
ROIC (12 months)32.9%
Positive free cash flow100% of years
How this category is measured

Score history

The full history of up to 20 years comes with MEQIRI Pro.

See plans

Crash risk high

How well MEQIRI warns

One of the 30% with the highest crash risk among smaller stocks.

From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.

What drives the risk

  • high price swings
  • price far below its 52-week high

What lowers it

  • solid fundamentals

Valuation

Valuation signal

Significantly undervalued
Price
$74.53
Fair value
$124.28
Gap to fair value
−40%

Closing price of 11 Nov 2026, used by the daily score.

In our model the price counts as cheap below $82.85 and expensive above $248.56 (uncertainty very high, based on the price swings of the past year).

The two parts of the fair value come to $203.21 (cash-flow model) and $45.35 (industry comparison), and the gap between them shows how uncertain the estimate is.

Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $105.47, at 7.8% it would be $152.64.

Valuation metrics

1.48
65.6
Fair value (model)
$124.28
Earnings part $45.35 (earnings per share $1.29 × 35.1)

Half from the cash-flow model, half from earnings times the industry P/E (35.1).

Calculate with your own assumptions

Company performance

This shows several years of history with an automatic assessment.

Revenue

14 years

In the twelve months to 30 Sep 2026, revenue rose 30% on the twelve months before. Revenue has grown strongly since 2012, at around 52% per year. From 2012 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.

Margins

14 years
  • Gross margin
  • Operating margin
  • Net margin

In fiscal 2025: gross 98%, operating 6%, net 13%. From 2012 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.

Debt & balance sheet

latest quarter
0.01
> 100x
3
Cash & equivalents
$370.7M

The balance sheet is solid, with low debt and comfortable interest coverage.

Earnings

Next earnings
23 Feb 2027in 103 days
Last reported
3 Nov 2026EPS reported $1.01 (expected $0.84)above expectations

Analyst estimates

Analysts have cut their 2027 earnings estimate by 3.1% since 15 Oct 2026. Falling estimates often precede bad news.

Fiscal 20264 analysts
Earnings per share
$2.07+1.8%
Revenue
$1.15B+3.2%
Fiscal 20274 analysts
Earnings per share
$4.17−3.1%
Revenue
$1.68B+5.5%

MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.

Company outlook raised

Share price after the results: +25.6%

2026 revenue guidance increased to $1.1 billion to $1.2 billion.

Supporting passage from the call, verbatim
“We expect growth to continue and have increased our 2026 revenue guidance to a range of $1.1 billion to $1.2 billion Net income was $43 million in the second quarter of 26, compared to net income of $35 million in the prior year period.”

The outlook is not part of the score and not a recommendation to buy or sell.

From the earnings call on 29 Jul 2026 (fiscal Q2 2026), read by AI.

Insiders

Open-market purchases and sales by executives, board members and major holders

All insider purchases

No open-market purchases in the last 6 months. 10 insiders sold, $83.01M in total.

Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.

  • Maduck SeanSale

    3 Nov 2026, Insider

    Shares
    13,159
    Price
    $82.25
    Value
    $1.08M
  • Maduck SeanSale

    2 Nov 2026, Insider

    Shares
    11,841
    Price
    $81.42
    Value
    $964,074
  • Vieira Roberto WandenkolkSale

    2 Nov 2026, President, Oncology

    Shares
    8,333
    Price
    $80.89
    Value
    $674,069
Show 36 more
  • Wilson James NSale

    15 Oct 2026, Board

    Shares
    10,000
    Price
    $114.81
    Value
    $1.15M
  • Vieira Roberto WandenkolkSale

    2 Oct 2026, President, Oncology

    Shares
    8,333
    Price
    $116.10
    Value
    $967,448
  • Lyon Joseph DouglasSale

    2 Oct 2026, See Remarks

    Shares
    9,190
    Price
    $116.13
    Value
    $1.07M
  • Maduck SeanSale

    2 Oct 2026, See Remarks

    Shares
    24,587
    Price
    $116.28
    Value
    $2.86M
  • Lyon Joseph DouglasSale

    1 Oct 2026, See Remarks

    Shares
    810
    Price
    $115.40
    Value
    $93,473
  • Maduck SeanSale

    1 Oct 2026, See Remarks

    Shares
    413
    Price
    $115.54
    Value
    $47,717
  • Vieira Roberto WandenkolkSale

    16 Sept 2026, President, Oncology

    Shares
    296
    Price
    $100.82
    Value
    $29,843
  • Wilson James NSale

    15 Sept 2026, Board

    Shares
    10,000
    Price
    $110.69
    Value
    $1.11M
  • Lyon Joseph DouglasSale

    14 Sept 2026, See Remarks

    Shares
    10,000
    Price
    $113.49
    Value
    $1.13M
  • Vieira Roberto WandenkolkSale

    2 Sept 2026, President, Oncology

    Shares
    58,333
    Price
    $110.76
    Value
    $6.46M
  • Maduck SeanSale

    1 Sept 2026, See Remarks

    Shares
    25,000
    Price
    $114.43
    Value
    $2.86M
  • Park KimberlySale

    26 Aug 2026, Board

    Shares
    26,685
    Price
    $122.55
    Value
    $3.27M
  • Maduck SeanSale

    25 Aug 2026, See Remarks

    Shares
    30,955
    Price
    $125.58
    Value
    $3.89M
  • Mahoney David LSale

    18 Aug 2026, Board

    Shares
    103,606
    Price
    $118.25
    Value
    $12.25M
  • Robb Gary CharlesSale

    17 Aug 2026, Chief Business Officer

    Shares
    10,000
    Price
    $116.26
    Value
    $1.16M
  • Maduck SeanSale

    14 Aug 2026, See Remarks

    Shares
    3,664
    Price
    $114.49
    Value
    $419,491
  • Wilson James NSale

    14 Aug 2026, Board

    Shares
    10,000
    Price
    $111.43
    Value
    $1.11M
  • Maduck SeanSale

    10 Aug 2026, See Remarks

    Shares
    1,031
    Price
    $114.52
    Value
    $118,068
  • Guyer WilliamSale

    10 Aug 2026, Chief Development Officer

    Shares
    16,300
    Price
    $113.43
    Value
    $1.85M
  • Guyer WilliamSale

    4 Aug 2026, Chief Development Officer

    Shares
    3,700
    Price
    $113.12
    Value
    $418,562
  • Maduck SeanSale

    3 Aug 2026, See Remarks

    Shares
    20,305
    Price
    $114.70
    Value
    $2.33M
  • Lyon Joseph DouglasSale

    3 Aug 2026, See Remarks

    Shares
    1,540
    Price
    $114.16
    Value
    $175,806
  • Mokari AtabakSale

    30 Jul 2026, Chief Financial Officer

    Shares
    80,000
    Price
    $114.71
    Value
    $9.18M
  • Wilson James NSale

    15 Jul 2026, Board

    Shares
    10,000
    Price
    $88.30
    Value
    $882,986
  • Mokari AtabakSale

    15 Jul 2026, Chief Financial Officer

    Shares
    40,000
    Price
    $87.71
    Value
    $3.51M
  • Guyer WilliamSale

    7 Jul 2026, Chief Development Officer

    Shares
    20,000
    Price
    $93.13
    Value
    $1.86M
  • Maduck SeanSale

    1 Jul 2026, See Remarks

    Shares
    25,000
    Price
    $88.35
    Value
    $2.21M
  • Mahoney David LSale

    17 Jun 2026, Board

    Shares
    20,000
    Price
    $84.53
    Value
    $1.69M
  • Wilson James NSale

    16 Jun 2026, Board

    Shares
    10,000
    Price
    $83.20
    Value
    $832,049
  • Mokari AtabakSale

    15 Jun 2026, Chief Financial Officer

    Shares
    40,000
    Price
    $81.15
    Value
    $3.25M
  • Guyer WilliamSale

    2 Jun 2026, Chief Development Officer

    Shares
    20,000
    Price
    $70.60
    Value
    $1.41M
  • Maduck SeanSale

    1 Jun 2026, See Remarks

    Shares
    25,000
    Price
    $70.21
    Value
    $1.76M
  • Mokari AtabakSale

    1 Jun 2026, Chief Financial Officer

    Shares
    40,000
    Price
    $70.00
    Value
    $2.8M
  • Belanoff Joseph KSale

    1 Jun 2026, Chief Executive Officer

    Shares
    12,837
    Price
    $69.74
    Value
    $895,252
  • Lyon Joseph DouglasSale

    27 May 2026, See Remarks

    Shares
    5,000
    Price
    $65.00
    Value
    $325,000
  • Maduck SeanSale

    27 May 2026, See Remarks

    Shares
    75,000
    Price
    $65.59
    Value
    $4.92M

Partial trades from one filing are shown in one row, with the average price.

Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.

What happened at Corcept Therapeutics

The key events of the last six months from our own data. A click takes you to the matching card.

Sector comparison

714 rated companies in Healthcare

Rank 83 of 714
83/ 714
This company
74
Sector median
53

Categories against the sector median

ProfitabilityMedian of 714 companies89 (median 37)52 above the median
GrowthMedian of 714 companies73 (median 53)20 above the median
FundamentalsMedian of 714 companies99 (median 46)53 above the median
ValuationMedian of 477 companies with a value51 (median 54)3 below the median
StabilityMedian of 714 companies77 (median 67)10 above the median
Capital allocationMedian of 714 companies80 (median 39)41 above the median
Technical analysisMedian of 714 companies47 (median 70)23 below the median
MomentumMedian of 714 companies56 (median 71)15 below the median

The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.

Competitors in Medical (Pharmaceuticals)

The next larger and next smaller companies by market value

All 17 Medical (Pharmaceuticals) stocks

ETFs that hold Corcept Therapeutics

Held by 10 ETFs on Xetra. Shown per index: the ETF with the largest weight.

ETFWeightCostFund size
State Street SPDR S&P 400 U.S. Mid Cap UCITS ETF (Acc)SPY40.20%0.30%€5.27B
iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG0.12%0.43%€2.48B
iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG0.07%0.35%€434.1M
Show 5 more
State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS0.07%0.45%€1.53B
State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV0.03%0.30%€944.34M
UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE0.02%0.25%€175.89M
Vanguard ESG Global All Cap UCITS ETF (USD) AccumulatingV3AA0.01%0.24%€1.69B
Vanguard FTSE Global All-Cap UCITS ETF Accum USDVGLA0.01%0.07%€3.9B

Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).

Data status and sources

Score
Daily value of 12 Nov 2026, recalculated nightly
Price
Closing price of 12 Nov 2026
Latest annual report
Fiscal year 2025, period end 31 Dec 2025
Source
Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Original filings at the SECReport a data error

Mandatory disclosures for this rating

  • ; time horizon around 12 months
  • Rated Strong, published since 7 Nov 2026 (in the score history since 4 Nov 2026)
  • Valuation signal Undervalued since 7 Nov 2026
  • End-of-day prices, metrics cached for up to 24 hours
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.
Full disclosures, methodology and data sourcesAll ratings of the last 12 monthsHow the score is calculated

MEQIRI counts visits without cookies. With your consent we remember for 90 days where you came from, also in your account, count page changes and time on page, recognise your next visit and load the Meta Pixel, which measures our advertising. You can withdraw your consent at any time under Cookie settings. Privacy